104 related articles for article (PubMed ID: 38719492)
1. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
Franchi M; Pellegrini G; Avogaro A; Buzzetti G; Candido R; Cavaliere A; Consoli A; Marzona I; Mennini FS; Palcic S; Corrao G
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38802266
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Wexler DJ; de Boer IH; Ghosh A; Younes N; Bebu I; Inzucchi SE; McGill JB; Mudaliar S; Schade D; Steffes MW; Tamborlane WV; Tan MH; Ismail-Beigi F;
JAMA Intern Med; 2023 Jul; 183(7):705-714. PubMed ID: 37213109
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
[TBL] [Abstract][Full Text] [Related]
7. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
8. Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
Shields BM; Dennis JM; Angwin CD; Warren F; Henley WE; Farmer AJ; Sattar N; Holman RR; Jones AG; Pearson ER; Hattersley AT;
Nat Med; 2023 Feb; 29(2):376-383. PubMed ID: 36477733
[TBL] [Abstract][Full Text] [Related]
9. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
[TBL] [Abstract][Full Text] [Related]
10. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
; Nathan DM; Lachin JM; Bebu I; Burch HB; Buse JB; Cherrington AL; Fortmann SP; Green JB; Kahn SE; Kirkman MS; Krause-Steinrauf H; Larkin ME; Phillips LS; Pop-Busui R; Steffes M; Tiktin M; Tripputi M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1075-1088. PubMed ID: 36129997
[TBL] [Abstract][Full Text] [Related]
11. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Deng Y; Polley EC; Wallach JD; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Lyon TD; Shah ND; Ross JS; McCoy RG
BMJ; 2022 Oct; 379():e070717. PubMed ID: 36191949
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
[TBL] [Abstract][Full Text] [Related]
13. ANALYSIS OF ANTIDIABETIC THERAPY FOR TYPE 2 DIABETES IN PRIMARY HEALTH CARE (WESTERN KAZAKHSTAN).
Bazargaliyev Y; Tleumagamabetova B; Kudabayeva K; Kosmuratova R
Georgian Med News; 2024 Mar; (348):22-27. PubMed ID: 38807384
[TBL] [Abstract][Full Text] [Related]
14. Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.
Buse JB; Nordahl Christensen H; Harty BJ; Mitchell J; Soule BP; Zacherle E; Cziraky M; Willey VJ
BMJ Open Diabetes Res Care; 2023 May; 11(3):. PubMed ID: 37137527
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.
Hong JL; Jonsson Funk M; Buse JB; Henderson LM; Lund JL; Pate V; Stürmer T
Epidemiology; 2017 May; 28(3):446-454. PubMed ID: 28166101
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes.
Shapiro SB; Yin H; Yu OHY; Azoulay L
Br J Clin Pharmacol; 2024 May; 90(5):1365-1370. PubMed ID: 38477518
[TBL] [Abstract][Full Text] [Related]
17. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study.
Bramante CT; Johnson SG; Garcia V; Evans MD; Harper J; Wilkins KJ; Huling JD; Mehta H; Alexander C; Tronieri J; Hong S; Kahkoska A; Alamgir J; Koraishy F; Hartman K; Yang K; Abrahamsen T; Stürmer T; Buse JB;
PLoS One; 2022; 17(11):e0271574. PubMed ID: 36395143
[TBL] [Abstract][Full Text] [Related]
18. Associations among diabetes medication use, serum magnesium, and insulin resistance in a cohort of older Puerto Rican adults.
Chen F; Mangano KM; Garelnabi M; Cardaleen K; Tucker KL
Am J Clin Nutr; 2024 Jun; 119(6):1523-1532. PubMed ID: 38599521
[TBL] [Abstract][Full Text] [Related]
19. A short-term economic evaluation of early insulin therapy compared to oral anti-diabetic drugs in order to reduce the major adverse events in type 2 diabetes patients in Iran.
Heshmat R; Darvishi A; Abdi Dezfouli R; Nikkhah A; Radmanesh R; Moslemi E
Curr Med Res Opin; 2024 May; 40(5):765-772. PubMed ID: 38533582
[TBL] [Abstract][Full Text] [Related]
20. Metformin: Past, Present, and Future.
Chaudhary S; Kulkarni A
Curr Diab Rep; 2024 Jun; 24(6):119-130. PubMed ID: 38568468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
